MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -118.94M | -80.77M | -54.80M | -40.68M | -36.01M |
| Total Depreciation and Amortization | 1.38M | 443.80K | 414.60K | 389.80K | 370.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.75M | 6.17M | 3.57M | 1.18M | -923.50K |
| Change in Net Operating Assets | -3.78M | -6.30M | -13.61M | -9.59M | -6.22M |
| Cash from Operations | -116.59M | -80.46M | -64.43M | -48.70M | -42.78M |
| Capital Expenditure | -519.60K | -628.60K | -496.40K | -496.40K | -284.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -205.08M | 59.23M | -173.56M | -73.14M | -24.90M |
| Cash from Investing | -205.60M | 58.60M | -174.06M | -73.64M | -25.18M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 52.78M | 83.80M | 83.71M | 534.99M | 482.45M |
| Repurchase of Common Stock | -100.00 | -100.00 | -100.00 | -100.00 | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.47M | -4.22M | -4.32M | -4.32M | -2.75M |
| Cash from Financing | 51.31M | 79.58M | 79.39M | 530.68M | 479.70M |
| Foreign Exchange rate Adjustments | 128.00K | -231.10K | 99.30K | -28.30K | -75.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -270.74M | 57.49M | -159.00M | 408.31M | 411.66M |
